CompletedPhase 2NCT01468909
Paclitaxel With or Without Pazopanib Hydrochloride in Treating Patients With Persistent or Recurrent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer
Studying Primary peritoneal carcinoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- National Cancer Institute (NCI)
- Principal Investigator
- Debra RichardsonNRG Oncology
- Intervention
- Laboratory Biomarker Analysis(other)
- Enrollment
- 106 enrolled
- Eligibility
- 18 years · FEMALE
- Timeline
- 2011 – 2018
Study locations (30)
- University of South Alabama Mitchell Cancer Institute, Mobile, Alabama, United States
- Gynecologic Oncology Group of Arizona, Phoenix, Arizona, United States
- Providence Saint Joseph Medical Center/Disney Family Cancer Center, Burbank, California, United States
- Gynecologic Oncology Associates-Newport Beach, Newport Beach, California, United States
- University of Connecticut, Farmington, Connecticut, United States
- Hartford Hospital, Hartford, Connecticut, United States
- Smilow Cancer Hospital Care Center at Saint Francis, Hartford, Connecticut, United States
- The Hospital of Central Connecticut, New Britain, Connecticut, United States
- Beebe Medical Center, Lewes, Delaware, United States
- Christiana Care Health System-Christiana Hospital, Newark, Delaware, United States
- Florida Hospital Orlando, Orlando, Florida, United States
- Women's Cancer Associates, St. Petersburg, Florida, United States
- Northeast Georgia Medical Center-Gainesville, Gainesville, Georgia, United States
- Central Georgia Gynecologic Oncology, Macon, Georgia, United States
- Memorial Health University Medical Center, Savannah, Georgia, United States
- +15 more locations on ClinicalTrials.gov
Collaborators
NRG Oncology
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT01468909 on ClinicalTrials.govOther trials for Primary peritoneal carcinoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1, PHASE2NCT07480954Dual-Targeting CAR-NK Cells for Recurrent Ovarian Cancer (MSLN, FRα, MUC16)Beijing Biotech
- RECRUITINGPHASE1, PHASE2NCT07322094CATALINA-4: A Study to Investigate the Safety and Efficacy of TORL-1-23 With Chemotherapy Given Before Initial Surgery in Women With Advanced Stage Ovarian CancerTORL Biotherapeutics, LLC
- RECRUITINGPHASE3NCT06915025Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal CancerImunon
- RECRUITINGPHASE2NCT07023484Personalized Timing of Interval Debulking Surgery in Advanced Ovarian CancerThe University of Hong Kong
- RECRUITINGPHASE2NCT06639074Folate Receptor Alpha Dendritic Cells (FRαDCs) or Placebo for the Treatment of Patients With Stage III or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer, FAROUT TrialMayo Clinic
- RECRUITINGPHASE1NCT06469281A Study to Learn if 27T51, a Mucin-16 (MUC16) Protein Targeting Immune Cell Therapy, Administered Alone or in Combination is Safe and How Well it Works for Adult Participants With Recurrent or Treatment Resistant Ovarian CancersRegeneron Pharmaceuticals
- RECRUITINGPHASE2NCT06492070Cryocompression With or Without Cilostazol for the Prevention of Paclitaxel-induced Neuropathy in Patients With Gynecological CancersEmory University
- RECRUITINGPHASE2NCT06434610A Study of B013 in Combination With Paclitaxel in Patients With Platinum-resistant Recurrent Ovarian Cancer.Shanghai Jiaolian Drug Research and Development Co., Ltd